A team of FDA officials and industry professionals working through Xavier Health has taken a major step towards forging the use of artificial intelligence (AI), by providing a Good Machine Learning Practices (GmLP) document for the evaluation and use of continuously learning systems (CLS).
FDA officials and leaders in the pharma and medical device spaces agree artificial intelligence (AI) tools could enable a step change in quality management in those industries. Areas that could be impacted include supply chain management, lot release, manufacturing, compliance operations, clinical trial end points, and drug discovery, among others.
In a fascinating podcast, Jon Speer, Founder and VP QA/RA, Greenlight Guru, interviews Marla Phillips, Director, Xavier Health, on AI explainability and why it matters in healthcare. As AI begins to transform how the pharma and medical device industries operate, overcome the media-generated hype and fear of AI to discover its benefits when using it responsibly.
Dr. Marla Phillips, Director, Xavier Health, took part in a panel discussion on Capitol Hill, July 17, 2018. The event was titled “AI Explainability: What that Means and Why It Matters in Healthcare.”
Xavier AI Initiative Core Team members Marla Phillips, Director, Xavier Health, Xavier University, and Mac McKeen, Fellow, Regulatory Science, Boston Scientific, will be speaking at the 122nd AFDO Annual Educational Conference.
Dr. Marla Phillips, Director, Xavier Health, and Cenk Undey, Amgen, presented at the IFPAC Annual Meeting, held in Bethesda, Maryland, February 11-14, 2018.
The Xavier AI Summit was a featured topic on Cincinnati Edition, a live interview program on Cincinnati Public Radio station WVXU, 91.7 FM.
IBM Watson Health and Xavier University announce a partnership to further the use of artificial intelligence within the healthcare industry.